| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Bergenin (Cuscutin) is a natural isocoumarin found in various medicinal plants. It shows mild anti-HIV activity,antihepatotoxic activity and antiulcer activity. It is trihydroxybenzoic acid glycoside and is the C-glycoside of 4-O-methyl gallic acid. It possesses an O-demethylated derivative called norbergenin. These are chemical compounds and drugs of Ayurveda, commonly known as Paashaanbhed. It shows a potent immunomodulatory effect.
| ln Vitro |
HeLa cervical cancer cells' viability is reduced by bergenin (7.5–30 µM; 24 hours) (IC50=15 µM)[1]. HeLa cervical cancer cells undergo apoptosis when exposed to bergenin (7.5-30 µM; 24 hours)[1].
|
|---|---|
| ln Vivo |
Mice that are pretreated with Bergenin (12.5–100 mg/kg; ip; once) exhibit a dose-related reduction of writhing caused by acetic acid[3].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HeLa cervical cancer cells Tested Concentrations: 7.5, 15, 30 µM Incubation Duration: 24 hrs (hours) Experimental Results: diminished the viability of HeLa cervical cancer cells. Cell Viability Assay[1] Cell Types: HeLa cervical cancer cells Tested Concentrations: 7.5, 15, 30 µM Incubation Duration: 24 hrs (hours) Experimental Results: Induced apoptosis in HeLa cervical cancer cells. |
| Animal Protocol |
Animal/Disease Models: Male Swiss Webster C57BL/6 mice[3]
Doses: 12.5, 25, 50, 100 mg/kg Route of Administration: ip; Once Experimental Results: Produced a dose-related inhibition of acetic acid-induced writhing in mice. |
| References |
[1]. Shi X, et al. Anticancer activity of bergenin against cervical cancer cells involves apoptosis, cell cycle arrest, inhibition of cell migration and the STAT3 signalling pathway. Exp Ther Med. 2019 May;17(5):3525-3529.
[2]. Yun J, et al. Bergenin decreases the morphine-induced physical dependence via antioxidative activity in mice. Arch Pharm Res. 2015 Jun;38(6):1248-54. [3]. de Oliveira CM, et al. Antinociceptive properties of bergenin. J Nat Prod. 2011 Oct 28;74(10):2062-8. |
| Molecular Formula |
C14H16O9
|
|
|---|---|---|
| Molecular Weight |
328.27
|
|
| CAS # |
477-90-7
|
|
| Related CAS # |
|
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@@]([H])([C@]2([H])[C@]1([H])C1=C(C(=C(C([H])=C1C(=O)O2)O[H])OC([H])([H])[H])O[H])O[H])O[H]
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0463 mL | 15.2314 mL | 30.4627 mL | |
| 5 mM | 0.6093 mL | 3.0463 mL | 6.0925 mL | |
| 10 mM | 0.3046 mL | 1.5231 mL | 3.0463 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA